Investigating preferences for oral nutritional supplements in cancer patients
Taste and Smell Alterations and Oral Nutritional Supplement (ONS) Preferences in Patients With Cancer
This study is trying to find out which flavors of nutritional drinks cancer patients prefer to help them eat better and feel healthier.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Bergen Academic / other |
| Locations | 1 site (Bergen, Vestland) |
| Trial ID | NCT05816369 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients diagnosed with cancer who are at high risk of malnutrition due to the disease and its treatments. It aims to assess the sensory preferences for different flavors of oral nutritional supplements (ONS) among these patients. By understanding which flavors are more acceptable, the study seeks to improve compliance with nutritional recommendations. Additionally, it will explore the relationship between taste and smell changes, dietary intake, malnutrition risk, and quality of life in cancer patients.
Who should consider this trial
Good fit: Ideal candidates for this study are ambulatory patients aged 18 and older diagnosed with lung cancer who are currently receiving cancer treatment.
Not a fit: Patients with severe cognitive disorders, those who cannot consume ONS, or terminally ill patients are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the nutritional support provided to cancer patients, improving their overall health and quality of life.
How similar studies have performed: While the specific approach of assessing sensory preferences for ONS in cancer patients may be novel, similar studies have shown the importance of nutritional support in improving patient outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ambulatory patients diagnosed with lung cancer * Patients receiving cancer treatment of different types * Age 18 years or more * Provided signed informed consent * Understand written and oral Norwegian Exclusion Criteria: * Severe mental or cognitive disorders * Contraindication to consume ONS (dysphagia, inability to swallow oral nutritional supplements) * Allergic or intolerant to any of the ingredients in the ONS * Terminally ill patients (\<3 months to live) * A clinically significant disease or condition that could, in the investigator's opinion make the patient unfit for the study
Where this trial is running
Bergen, Vestland
- University of Bergen — Bergen, Vestland, Norway (Recruiting)
Study contacts
- Principal investigator: Simon N Dankel, Professor — University of Bergen
- Study coordinator: Simon N Dankel, Professor
- Email: simon.dankel@uib.no
- Phone: +47 943 08 637
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.